From 6bcf7df0b3f07e304a89f68566a1259468bdc38a Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:17:10 +0000 Subject: [PATCH] auto-fix: strip 2 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- 2 files changed, 2 insertions(+), 2 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 50f2b5d4..bf3d0570 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -79,7 +79,7 @@ Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* BALANCE Model's dual payment mechanism (capitation adjustment + reinsurance) plus manufacturer-funded lifestyle support represents the first major policy attempt to address the chronic-use cost structure. The Medicare GLP-1 Bridge (July 2026) provides immediate price relief while full model architecture is built, indicating urgency around cost containment. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1a2e85d0..40852332 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -67,7 +67,7 @@ Digital behavioral support may partially solve the persistence problem: UK study ### Additional Evidence (extend) -*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16* +*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16* BALANCE Model's manufacturer-funded lifestyle support requirement directly addresses the persistence problem by mandating evidence-based programs for GI side effects, nutrition, and physical activity—the factors most associated with discontinuation. This shifts the cost of adherence support from payers to manufacturers.